Modulation of TNF-α gene expression by IFN-γ and pamidronate in murine macrophages: Regulation by STAT1-dependent pathways

Journal of Immunology

Volumn 174, Issue 4, 2005, Pages 1801-1810

  Takagi, Kae ^b   Takagi, Masatoshi ^c   Kanangat, Siva ^a,b   Warrington, Kenneth J ^b   Shigemitsu, Hidenobu ^a,b   Postlethwaite, Arnold E ^a,b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PAMIDRONIC ACID; PROTEIN TYROSINE PHOSPHATASE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME INHIBITION; GENE EXPRESSION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 13544258086     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.4.1801     Document Type: Article

References (60)

1. Rogers, M. J., S. Gordon, H. L. Benford, F. P. Coxon, S. P. Luckman, J. Monkkonen, and J. C. Frith. 2000. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961.
2. Mundy, G. R., and T. Yoneda. 1998. Bisphosphonates as anticancer drugs. N. Engl. J. Med. 339:398.
3. Adami, S., A. K. Bhalla, R. Dorizzi, F. Montesanti, S. Rosini, G. Salvagno, and V. Lo Cascio. 1987. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 41:326.
4. Adami, S., and N. Zamberlan. 1996. Adverse effects of bisphosphonates: a comparative review. Drug Safety 14:158.
5. Schweitzer, D. H., M. Oostendorp-van de Ruit, G. Van der Pluijm, C. W. Lowik, and S. E. Papapoulos. 1995. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J. Bone Miner. Res. 10:956.
6. Sauty, A., M. Pecherstorfer, I. Zimmer-Roth, P. Fioroni, L. Juillerat, M. Markert, H. Ludwig, P. Leuenberger, P. Burckhardt, and D. Thiebaud. 1996. Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133.
7. Thiebaud, D., A. Sauty, P. Burckhardt, P. Leuenberger, L. Sitzler, J. R. Green, A. Kandra, J. Zieschang, and P. Ibarra de Palacios. 1997. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif. Tissue Int. 61:386.
8. Santini, D., B. Vincenzi, G. Avvisati, G. Dicuonzo, F. Battistoni, M. Gavasci, A. Salerno, V. Denaro, and G. Tonini. 2002. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res. 8:1080.
9. Pietschmann, P., P. Stohlawetz, S. Brosch, G. Steiner, J. S. Smolen, and M. Peterlik. 1998. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif. Tissue Int. 63:325.
10. Pennanen, N., S. Lapinjoki, A. Urtti, and J. Monkkonen. 1995. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. Pharm. Res. 12:916.
11. Sugawara, S., M. Shibazaki, H. Takada, H. Kosugi, and Y. Endo. 1998. Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice. Br. J. Pharmacol. 125:735.
12. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15:749.
13. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415.
14. Darnell, J. E., Jr. 1997. STATs and gene regulation. Science 277:1630.
15. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431.
16. Ihle, J. N., B. A. Witthuhn, F. W. Quelle, K. Yamamoto, W. E. Thierfelder, B. Kreider, and O. Silvennoinen. 1994. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem. Sci. 19:222.
17. Ihle, J. N. 1995. Cytokine receptor signalling. Nature 377:591.
18. Ramana, C. V., M. P. Gil, R. D. Schreiber, and G. R. Stark. 2002. Stat1-dependent and -independent pathways in IFN-γ-dependent signaling. Trends Immunol. 23:96.
19. Vilcek, J., and T. H. Lee. 1991. Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J. Biol. Chem. 266:7313.
20. Ruddle, N. H. 1992. Tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β). Curr. Opin. Immunol. 4:327.
21. Meltzer, M. S., M. Occhionero, and L. P. Ruco. 1982. Macrophage activation for tumor cytotoxicity: regulatory mechanisms for induction and control of cytotoxic activity. Fed. Proc. 41:2198.
22. Alleva, D. G., E. B. Johnson, F. M. Lio, S. A. Boehme, P. J. Conlon, and P. D. Crowe. 2002. Regulation of murine macrophage proinflammatory and antiinflammatory cytokines by ligands for peroxisome proliferator-activated receptor-γ: counter-regulatory activity by IFN-γ. J. Leukocyte Biol. 71:677.
23. Frei, K., C. Siepl, P. Groscurth, S. Bodmer, C. Schwerdel, and A. Fontana. 1987. Antigen presentation and tumor cytotoxicity by interferon-γ-treated microglial cells. Eur. J. Immunol. 17:1271.
24. Schook, L. B., H. Albrecht, P. Gallay, and C. V. Jongeneel. 1994. Cytokine regulation of TNF-α mRNA and protein production by unprimed macrophages from C57BL/6 and NZW mice. J. Leukocyte Biol. 56:514.
25. Rendon-Mitchell, B., M. Ochani, J. Li, J. Han, H. Wang, H. Yang, S. Susarla, C. Czura, R. A. Mitchell, G. Chen, et al. 2003. IFN-γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170:3890.
26. Rose, D. M., B. W. Winston, E. D. Chan, D.W. Riches, and P. M. Henson. 1997. Interferon-γ and transforming growth factor-β modulate the activation of mitogen-activated protein kinases and tumor necrosis factor-α production induced by Fcγ-receptor stimulation in murine macrophages. Biochem. Biophys. Res. Commun. 238:256.
27. Hayes, M. P., S. L. Freeman, and R. P. Donnelly. 1995. IFN-γ priming of monocytes enhances LPS-induced TNF production by augmenting both transcription and MRNA stability. Cytokine 7:427.
28. Nguyen, V. T., and E. N. Benveniste. 2002. Critical role of tumor necrosis factor-α and NF-κB in interferon-γ-induced CD40 expression in microglia/macrophages. J. Biol. Chem. 277:13796.
29. Yao, J., N. Mackman, T. S. Edgington, and S. T. Fan. 1997. Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells: regulation by Egr-1, c-Jun, and NF-κB transcription factors. J. Biol. Chem. 272:17795.
30. Raabe, T., M. Bukrinsky, and R. A. Currie. 1998. Relative contribution of transcription and translation to the induction of tumor necrosis factor-α by lipopolysaccharide. J. Biol. Chem. 273:974.
31. Liu, H., P. Sidiropoulos, G. Song, L. J. Pagliari, M. J. Birrer, B. Stein, J. Anrather, and R. M. Pope. 2000. TNF-α gene expression in macrophages: regulation by NF-κB is independent of c-Jun or C/EBPβ. J. Immunol. 164:4277.
32. Ohmori, Y., and T. A. Hamilton. 2001. Requirement for STAT1 in LPS-induced gene expression in macrophages. J. Leukocyte Biol. 69:598.
33. Makkonen, N., A. Salminen, M. J. Rogers, J. C. Frith, A. Urtti, E. Azhayeva, and J. Monkkonen. 1999. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur. J. Pharm. Sci. 8:109.
34. Senzer, N., S. Mani, A. Rosemurgy, J. Nemunaitis, C. Cunningham, C. Guha, N. Bayol, M. Gillen, K. Chu, C. Rasmussen, et al. 2004. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor α gene: a phase I study in patients with solid tumors. J. Clin. Oncol. 22:592.
35. Mueller, H. 1998. Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell. Mol. Life Sci. 54:1291.
36. Curnis, F., A. Sacchi, and A. Corti. 2002. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110:475.
37. Lejeune, F. J. 2002. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J. Clin. Invest. 110:433.
38. Unkeless, J. C., S. Gordon, and E. Reich. 1974. Secretion of plasminogen activator by stimulated macrophages. J. Exp. Med. 139:834.
39. Thompson, J. E., R. M. Cubbon, R. T. Cummings, L. S. Wicker, R. Frankshun, B. R. Cunningham, P. M. Cameron, P. T. Meinke, N. Liverton, Y. Weng, et al. 2002. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12:1219.
40. Lin, Y. Z., S. Y. Yao, R. A. Veach, T. R. Torgerson, and J. Hawiger. 1995. Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 270:14255.
41. Wu, T. R., Y. K. Hong, X. D. Wang, M. Y. Ling, A. M. Dragoi, A. S. Chung, A. G. Campbell, Z. Y. Han, G. S. Feng, and Y. E. Chin. 2002. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem. 277:47572.
42. Ramana, C. V., M. Chatterjee-Kishore, H. Nguyen, and G. R. Stark. 2000. Complex roles of Stat1 in regulating gene expression. Oncogene 19:2619.
43. ten Hoeve, J., M. de Jesus Ibarra-Sanchez, Y. Fu, W. Zhu, M. Tremblay, M. David, and K. Shuai. 2002. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell. Biol. 22:5662.
44. Osman, F., N. Jarrous, Y. Ben-Asouli, and R. Kaempfer. 1999. A cis-acting element in the 3′-untranslated region of human TNF-α mRNA renders splicing dependent on the activation of protein kinase PKR. Genes Dev. 13:3280.
45. Brook, M., G. Sully, A. R. Clark, and J. Saklatvala. 2000. Regulation of tumour necrosis factor α mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett. 483:57.
46. Beutler, B., V. Tkacenko, I. Milsark, N. Krochin, and A. Cerami. 1986. Effect of γ interferon on cachectin expression by mononuclear phagocytes: reversal of the lpsd (endotoxin resistance) phenotype. J. Exp. Med. 164:1791.
47. Lee, J. Y., and K. E. Sullivan. 2001. γ Interferon and lipopolysaccharide interact at the level of transcription to induce tumor necrosis factor α expression. Infect. Immun. 69:2847.
48. Narumi, S., J. H. Finke, and T. A. Hamilton. 1990. Interferon γ and interleukin 2 synergize to induce selective monokine expression in murine peritoneal macrophages. J. Biol. Chem. 265:7036.
49. Narumi, S., J. M. Tebo, J. H. Finke, and T. A. Hamilton. 1992. IFN-γ and IL-2 cooperatively activate NFκB in murine peritoneal macrophages. J. Immunol. 149:529.
50. Kotenko, S. V., and S. Pestka. 2000. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19:2557.
51. Aoki, N., S. Ueno, H. Mano, S. Yamasaki, M. Shiota, H. Miyazaki, Y. Yamaguchi-Aoki, T. Matsuda, and A. Ullrich. 2004. Mutual regulation of protein-tyrosine phosphatase 20 and protein-tyrosine kinase Tec activities by tyrosine phosphorylation and dephosphorylation. J. Biol. Chem. 279:10765.
52. Zhao, Z., Z. Tan, J. H. Wright, C. D. Diltz, S. H. Shen, E. G. Krebs, and E. H. Fischer. 1995. Altered expression of protein-tyrosine phosphatase 2C in 293 cells affects protein tyrosine phosphorylation and mitogen-activated protein kinase activation. J. Biol. Chem. 270:11765.
53. Schmidt, A., S. J. Rutledge, N. Endo, E. E. Opas, H. Tanaka, G. Wesolowski, C. T. Leu, Z. Huang, C. Ramachandaran, S. B. Rodan, et al. 1996. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Natl. Acad. Sci. USA 93:3068.
54. Skorey, K., H. D. Ly, J. Kelly, M. Hammond, C. Ramachandran, Z. Huang, M. J. Gresser, and Q. Wang. 1997. How does alendronate inhibit protein-tyrosine phosphatases? J. Biol. Chem. 272:22472.
55. Opas, E. E., S. J. Rutledge, E. Golub, A. Stern, Z. Zimolo, G. A. Rodan, and A. Schmidt. 1997. Alendronate inhibition of protein-tyrosine-phosphatase- meg1. Biochem. Pharmacol. 54:721.
56. Endo, N., S. J. Rutledge, E. E. Opas, R. Vogel, G. A. Rodan, and A. Schmidt. 1996. Human protein tyrosine phosphatase-σ: alternative splicing and inhibition by bisphosphonates. J. Bone Miner. Res. 11:535.
57. Murakami, H., N. Takahashi, S. Tanaka, I. Nakamura, N. Udagawa, S. Nakajo, K. Nakaya, M. Abe, Y. Yuda, F. Konno, et al. 1997. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 20:399.
58. Wang, L., A. Kamath, H. Das, L. Li, and J. F. Bukowski. 2001. Antibacterial effect of human Vγ2Vδ2 T cells in vivo. J. Clin. Invest. 108:1349.
59. Das, H., L. Wang, A. Kamath, and J. F. Bukowski. 2001. Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98:1616.
60. Clezardin, P. 2002. The antitumor potential of bisphosphonates. Semin. Oncol. 29:33.